<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f720f76-1728-e099-e063-6294a90ac35b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Calcium Acetate Capsules safely and effectively. See full prescribing information for Calcium Acetate Capsules.
 <br/>
      <br/>
CALCIUM ACETATE capsules, 667 mg, for oral use.
 <br/>
Initial U.S. Approval: 1990
</title>
   <effectiveTime value="20250303"/>
   <setId root="89a2ee04-1024-4a81-ba0d-a6655d529827"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f72130d-4072-e56f-e063-6294a90a2496"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250303"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-4299" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>calcium acetate</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>calcium acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="23155-531" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="667"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y882YXF34X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CALCIUM ACETATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2M83C4R6ZB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CALCIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-4299-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA202315" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250302"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="23" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">HP531</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="2f720f76-1729-e099-e063-6294a90ac35b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Calcium acetate capsule is a phosphate binder indicated for the reduction of serum phosphorus in patients with end stage renal disease. (
  
     <linkHtml href="#ID1">1</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID4">
                     <id root="2f720f76-172a-e099-e063-6294a90ac35b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID5">Calcium acetate capsule is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD).</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID6">
               <id root="2f720f76-172b-e099-e063-6294a90ac35b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Starting dose is 2 capsules with each meal. (
  
     <linkHtml href="#ID6">2</linkHtml>)
 
    </item>
                           <item>Titrate the dose every 2 to 3 weeks until acceptable serum phosphorus level is reached. Most patients require 3 to 4 capsules with each meal.(
  
     <linkHtml href="#ID6">2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID9">
                     <id root="2f720f76-172c-e099-e063-6294a90ac35b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID10">The recommended initial dose of calcium acetate capsules for the adult dialysis patient is 2 capsules with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 capsules with each meal.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID11">
               <id root="2f720f76-172d-e099-e063-6294a90ac35b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20250303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Capsule: 667 mg calcium acetate capsule.(
  
     <linkHtml href="#ID11">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID14">
                     <id root="2f720f76-172e-e099-e063-6294a90ac35b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID15">Capsule: 667 mg calcium acetate per capsule.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID16">
               <id root="2f720f76-172f-e099-e063-6294a90ac35b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID89">Patients with hypercalcemia.</paragraph>
               </text>
               <effectiveTime value="20250303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypercalcemia. (
  
     <linkHtml href="#ID16">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID21">
               <id root="2f720f76-1730-e099-e063-6294a90ac35b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Treat mild hypercalcemia by reducing or interrupting calcium acetate and Vitamin D. Severe hypercalcemia may require hemodialysis and discontinuation of calcium acetate capsules. (
  
     <linkHtml href="#ID24">5.1</linkHtml>)
 
    </item>
                           <item>Hypercalcemia may aggravate digitalis toxicity. (
  
     <linkHtml href="#ID26">5.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID24">
                     <id root="2f720f76-1731-e099-e063-6294a90ac35b"/>
                     <title>5.1

 <content styleCode="italics">Hypercalcemia</content>
                     </title>
                     <text>
                        <paragraph ID="ID25">Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate. Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with calcium acetate.</paragraph>
                        <paragraph>An overdose of calcium acetate may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the calcium acetate dosage or discontinue the treatment, depending on the severity of hypercalcemia.</paragraph>
                        <paragraph>More severe hypercalcemia (Ca&gt;12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing calcium acetate therapy.</paragraph>
                        <paragraph>Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the calcium acetate dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.</paragraph>
                        <paragraph>Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of calcium acetate on the progression of vascular or soft tissue calcification has not been determined.</paragraph>
                        <paragraph>Hypercalcemia (&gt;11 mg/dL) was reported in 16% of patients in a 3-month study of a solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.</paragraph>
                        <paragraph>Maintain the serum calcium-phosphorus (Ca x P) product below 55 mg
 
  <sup>2</sup>/dL
 
  <sup>2</sup>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID26">
                     <id root="2f720f76-1732-e099-e063-6294a90ac35b"/>
                     <title>5.2

 <content styleCode="italics">Concomitant Use with Medications</content>
                     </title>
                     <text>
                        <paragraph ID="ID27">Hypercalcemia may aggravate digitalis toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID28">
               <id root="2f720f76-1733-e099-e063-6294a90ac35b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The most common (&gt;10%) adverse reactions are hypercalcemia, nausea, and vomiting. (
  
     <linkHtml href="#ID34">6.1</linkHtml>).
 
    </item>
                           <item>In clinical studies, patients have occasionally experienced nausea during calcium acetate therapy. (
  
     <linkHtml href="#ID28">6</linkHtml>).
 
    </item>
                        </list>
                        <paragraph ID="ID31">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID32">
                     <id root="2f720f76-1734-e099-e063-6294a90ac35b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID33">Hypercalcemia is discussed elsewhere [see
 
  <linkHtml href="#ID24">Warnings and Precautions (5.1)</linkHtml>].

 </paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID34">
                     <id root="2f720f76-1735-e099-e063-6294a90ac35b"/>
                     <title>6.1

 <content styleCode="italics">Clinical Trial Experience</content>
                     </title>
                     <text>
                        <paragraph ID="ID35">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In clinical studies, calcium acetate has been generally well tolerated.</paragraph>
                        <paragraph>Calcium acetate was studied in a 3-month, open-label, non-randomized study of 98 enrolled ESRD hemodialysis patients and in a two week double-blind, placebo-controlled, cross-over study with 69 enrolled ESRD hemodialysis patients. Adverse reactions (&gt;2% on treatment) from these trials are presented in Table 1.</paragraph>
                        <table ID="ID36" width="100%" styleCode="Noautorules">
                           <caption>   Table 1: Adverse Reactions in Patients with End-Stage Renal Disease Undergoing Hemodialysis</caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold"> Preferred Term</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold"> Total adverse reactions reported for</content>
                                    <br/>
                                    <content styleCode="bold"> calcium acetate</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold"> 3 – mo</content>,
    
     <content styleCode="bold"> open-label study of calcium acetate</content>
                                    <br/>
                                    <content styleCode="bold"> n = 98</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                                    <content styleCode="bold"> Double-blind</content>,
    
     <content styleCode="bold"> placebo-controlled</content>,
    
     <content styleCode="bold"> cross over study of calcium acetate</content>
                                    <br/>
                                    <content styleCode="bold"> n = 69</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" valign="top"/>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">
                                    <content styleCode="bold"> n = 167</content>
                                    <br/>   n (%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">n (%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">
                                    <content styleCode="bold"> Calcium acetate</content>
                                    <br/>   n (%) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>   n (%) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Botrule Rrule" valign="top">Nausea 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">6 (3.6) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">6 (6.1) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">0 (0.0) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">0 (0.0) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Botrule Rrule" valign="top">Vomiting 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">4 (2.4) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">4 (4.1) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">0 (0.0) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">0 (0.0) 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Botrule Rrule" valign="top">Hypercalcemia 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">21 (12.6) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">16 (16.3) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">5 (7.2) 
     <br/>
                                 </td>
                                 <td align="center" styleCode=" Botrule Rrule" valign="top">0 (0.0) 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID37">Mild hypercalcemia may be asymptomatic or manifest itself as constipation, anorexia, nausea, and vomiting. More severe hypercalcemia is associated with confusion, delirium, stupor, and coma. Decreasing dialysate calcium concentration could reduce the incidence and severity of calcium acetate-induced hypercalcemia. Isolated cases of pruritus have been reported, which may represent allergic reactions.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID38">
                     <id root="2f720f76-1736-e099-e063-6294a90ac35b"/>
                     <title>6.2

 <content styleCode="italics">Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph ID="ID39">Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or to establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>The following additional adverse reactions have been identified during post-approval of calcium acetate: dizziness, edema, and weakness.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID40">
               <id root="2f720f76-1737-e099-e063-6294a90ac35b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250303"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Calcium acetate capsule may decrease the bioavailability of tetracyclines or fluoroquinolones
  
     <content styleCode="bold">.</content>(
  
     <linkHtml href="#ID40">7</linkHtml>)
 
    </item>
                           <item>When clinically significant drug interactions are expected, administer the drug at least one hour before or at least three hours after calcium acetate capsule, or consider monitoring blood levels of the drug. (
  
     <linkHtml href="#ID40">7</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID43">
                     <id root="2f720f76-1738-e099-e063-6294a90ac35b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID44">The drug interaction of calcium acetate is characterized by the potential of calcium to bind to drugs with anionic functions (e.g., carboxyl and hydroxyl groups). Calcium acetate capsule may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism.</paragraph>
                        <paragraph>There are no empirical data on avoiding drug interactions between calcium acetate and most concomitant drugs. When administering an oral medication with calcium acetate where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, administer the drug one hour before or three hours after calcium acetate. Monitor blood levels of the concomitant drugs that have a narrow therapeutic range. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials with all forms of calcium acetate.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID45">
                     <id root="2f720f76-1739-e099-e063-6294a90ac35b"/>
                     <title>7.1

 <content styleCode="italics">Ciprofloxacin</content>
                     </title>
                     <text>
                        <paragraph ID="ID46">In a study of 15 healthy subjects, a co-administered single dose of 4 calcium acetate tablets approximately 2.7 g, decreased the bioavailability of ciprofloxacin by approximately 50%.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID47">
               <id root="2f720f76-173a-e099-e063-6294a90ac35b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250303"/>
               <component>
                  <section ID="ID48">
                     <id root="2f720f76-173b-e099-e063-6294a90ac35b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1

 <content styleCode="italics">PREGNANCY</content>
                     </title>
                     <text>
                        <paragraph ID="ID49">Pregnancy Category C</paragraph>
                        <paragraph>Calcium acetate capsules contains calcium acetate. Animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. Patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID24">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>. Maintenance of normal serum calcium levels is important for maternal and fetal well being.  Hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. Calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment.

 </paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID50">
                     <id root="2f720f76-173c-e099-e063-6294a90ac35b"/>
                     <title>8.2

 <content styleCode="italics">LABOR &amp; DELIVERY</content>
                     </title>
                     <text>
                        <paragraph ID="ID51">The effects of calcium acetate on labor and delivery are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID90">
                     <id root="2f720f76-173d-e099-e063-6294a90ac35b"/>
                     <title>8.3

 <content styleCode="italics">NURSING MOTHERS</content>
                     </title>
                     <text>
                        <paragraph ID="ID91">Calcium acetate capsule contains calcium acetate and is excreted in human milk. Human milk feeding by a mother receiving calcium acetate is not expected to harm an infant, provided maternal serum calcium levels are appropriately monitored.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID54">
                     <id root="2f720f76-173e-e099-e063-6294a90ac35b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4

 <content styleCode="italics">PEDIATRIC USE</content>
                     </title>
                     <text>
                        <paragraph ID="ID55">Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID56">
                     <id root="2f720f76-173f-e099-e063-6294a90ac35b"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5

 <content styleCode="italics">GERIATRIC USE</content>
                     </title>
                     <text>
                        <paragraph ID="ID57">Clinical studies of calcium acetate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID58">
               <id root="2f720f76-1740-e099-e063-6294a90ac35b"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID59">Administration of calcium acetate capsule in excess of the appropriate daily dosage may result in hypercalcemia
 
  <content styleCode="italics">[see
  
   <linkHtml href="#ID24">Warnings and Precautions (5.1)</linkHtml>].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250303"/>
            </section>
         </component>
         <component>
            <section ID="ID60">
               <id root="2f720f76-1741-e099-e063-6294a90ac35b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID61">Calcium acetate, USP acts as a phosphate binder. Its chemical name is calcium acetate. Its molecular formula is C
 
  <sub>4</sub>H
 
  <sub>6</sub>CaO
 
  <sub>4</sub>, and its molecular weight is 158.17. Its structural formula is:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L4dd992f4-8425-4f9b-8daf-8305c5f4d071"/>
                  </paragraph>
                  <paragraph ID="ID63">Calcium acetate capsules, USP are hard gelatin capsules with blue opaque cap and body both imprinted "HP 531" in black ink. Each capsule contains 667 mg calcium acetate, USP (anhydrous; Ca(CH
 
  <sub>3</sub>COO)
 
  <sub>2</sub>; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium and following inactive ingredients crospovidone, FD&amp;C Blue No. 1, FD&amp;C Blue No. 3, gelatin, magnesium stearate, sodium lauryl sulfate and titanium dioxide. In addition to the ingredients listed above, each capsule contains following inactive ingredients from imprinting ink: butyl alcohol, iron oxide black, propylene glycol and shellac.

 </paragraph>
                  <paragraph>FDA approved dissolution test specifications differ from USP.</paragraph>
               </text>
               <effectiveTime value="20250303"/>
               <component>
                  <observationMedia ID="L4dd992f4-8425-4f9b-8daf-8305c5f4d071">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID64">
               <id root="2f720f76-1742-e099-e063-6294a90ac35b"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph ID="ID65">Patients with ESRD retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. Hyperphosphatemia also plays a role in the development of secondary hyperparathyroidism in patients with ESRD.</paragraph>
               </text>
               <effectiveTime value="20250303"/>
               <component>
                  <section ID="ID66">
                     <id root="2f720f76-1743-e099-e063-6294a90ac35b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1

 <content styleCode="italics">MECHANISM OF ACTION</content>
                     </title>
                     <text>
                        <paragraph ID="ID67">Calcium acetate, when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
               <component>
                  <section ID="ID68">
                     <id root="2f720f76-1744-e099-e063-6294a90ac35b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2

 <content styleCode="italics">PHARMACODYNAMICS</content>
                     </title>
                     <text>
                        <paragraph ID="ID69">Orally administered calcium acetate from pharmaceutical dosage forms is systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non-fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID70">
               <id root="2f720f76-1745-e099-e063-6294a90ac35b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250303"/>
               <component>
                  <section ID="ID92">
                     <id root="2f720f76-1746-e099-e063-6294a90ac35b"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID93">No carcinogenicity, mutagenicity, or fertility studies have been conducted with calcium acetate.</paragraph>
                     </text>
                     <effectiveTime value="20250303"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID73">
               <id root="2f720f76-1747-e099-e063-6294a90ac35b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID74">Effectiveness of calcium acetate in decreasing serum phosphorus has been demonstrated in two studies of the calcium acetate solid dosage form.</paragraph>
                  <paragraph>Ninety-one patients with end-stage renal disease who were undergoing hemodialysis and were hyperphosphatemic (serum phosphorus &gt;5.5 mg/dL) following a 1-week phosphate binder washout period contributed efficacy data to an open-label, non-randomized study.</paragraph>
                  <paragraph>The patients received calcium acetate 667 mg tablets at each meal for a period of 12 weeks. The initial starting dose was 2 tablets per meal for 3 meals a day, and the dose was adjusted as necessary to control serum phosphorus levels. The average final dose after 12 weeks of treatment was 3.4 tablets per meal. Although there was a decrease in serum phosphorus, in the absence of a control group the true magnitude of effect is uncertain.</paragraph>
                  <paragraph>The data presented in Table 2 demonstrate the efficacy of calcium acetate in the treatment of hyperphosphatemia in end-stage renal disease patients. The effects on serum calcium levels are also presented.</paragraph>
                  <table ID="ID75" width="100%" styleCode="Noautorules">
                     <caption>   Table 2: Average Serum Phosphorous and Calcium Levels at Pre-Study, Interim and Study Completion Time points</caption>
                     <col width="16%"/>
                     <col width="16%"/>
                     <col width="16%"/>
                     <col width="16%"/>
                     <col width="16%"/>
                     <col width="16%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="6">
                              <paragraph styleCode="Footnote">
                                 <sup>a</sup>Values expressed as mean ± SE.
    
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="6">
                              <paragraph styleCode="Footnote">
                                 <sup>b</sup>Ninety-one patients completed at least 6 weeks of the study.
    
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="6">
                              <paragraph styleCode="Footnote">
                                 <sup>c</sup>ANOVA of difference in values at pre-study and study completion
    
     </paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Lrule Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold"> Parameter</content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold"> Pre-Study</content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold"> Week 4
     
      <sup>b</sup>
                              </content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold"> Week 8</content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold"> Week 12</content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold"> p-value
     
      <sup>c</sup>
                              </content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Lrule Botrule Rrule" valign="top"> Phosphorus (mg/dL)
    
     <content styleCode="bold">
                                 <sup>a</sup>
                              </content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">7.4 ± 0.17 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">5.9 ± 0.16 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">5.6 ± 0.17 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">5.2 ± 0.17 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">≤0.01 
     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Lrule Botrule Rrule" valign="top"> Calcium (mg/dL)
    
     <content styleCode="bold">
                                 <sup>a</sup>
                              </content>
                              <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">8.9 ± 0.09 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">9.5 ± 0.10 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">9.7 ± 0.10 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">9.7 ± 0.10 
     <br/>
                           </td>
                           <td align="center" styleCode=" Botrule Rrule" valign="top">≤0.01 
     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID76">There was a 30% decrease in serum phosphorus levels during the 12 week study period (p&lt;0.01). Two-thirds of the decline occurred in the first month of the study. Serum calcium increased 9% during the study mostly in the first month of the study.</paragraph>
                  <paragraph>Treatment with the phosphate binder was discontinued for patients from the open-label study, and those patients whose serum phosphorus exceeded 5.5 mg/dL were eligible for entry into a double-blind, placebo-controlled, cross-over study. Patients were randomized to receive calcium acetate or placebo, and each continued to receive the same number of tablets as had been individually established during the previous study. Following 2 weeks of treatment, patients switched to the alternative therapy for an additional 2 weeks.</paragraph>
                  <paragraph>The phosphate binding effect of calcium acetate is shown in the Table 3.</paragraph>
               </text>
               <effectiveTime value="20250303"/>
            </section>
         </component>
         <component>
            <section ID="ID79">
               <id root="2f720f76-1748-e099-e063-6294a90ac35b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Calcium Acetate Capsules, USP are blue opaque capsules imprinted with "HP 531" for oral administration containing 667 mg calcium acetate (anhydrous Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium.</paragraph>
                  <paragraph/>
                  <paragraph>NDC: 70518-4299-00</paragraph>
                  <paragraph>PACKAGING: 30 in 1 BLISTER PACK</paragraph>
                  <paragraph/>
                  <paragraph>STORAGE:  Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250303"/>
            </section>
         </component>
         <component>
            <section ID="ID81">
               <id root="2f721268-240f-44ec-e063-6394a90ac78a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Inform patients to take calcium acetate capsules with meals, adhere to their prescribed diets, and avoid the use of calcium supplements including nonprescription antacids. Inform the patients about the symptoms of hypercalcemia 
  <content styleCode="italics">[see 
   <linkHtml href="#ID24">Warnings and Precautions (5.1)</linkHtml>and 
   <linkHtml href="#ID34">Adverse Reactions (6.1)</linkHtml>]. 
  </content>
                  </paragraph>
                  <paragraph>Advise patients who are taking an oral medication where reduction in the bioavailability of that medication would have clinically significant effect on its safety and efficacy to take the drug one hour before or three hours after calcium acetate capsules.</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                  <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                  <paragraph>(724) 465-8762</paragraph>
               </text>
               <effectiveTime value="20250303"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2f720f76-174a-e099-e063-6294a90ac35b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: calcium acetate</paragraph>
                  <paragraph>GENERIC: calcium acetate</paragraph>
                  <paragraph>DOSAGE: CAPSULE</paragraph>
                  <paragraph>ADMINSTRATION: ORAL</paragraph>
                  <paragraph>NDC: 70518-4299-0</paragraph>
                  <paragraph>COLOR: blue</paragraph>
                  <paragraph>SHAPE: CAPSULE</paragraph>
                  <paragraph>SCORE: No score</paragraph>
                  <paragraph>SIZE: 23 mm</paragraph>
                  <paragraph>IMPRINT: HP531</paragraph>
                  <paragraph>PACKAGING: 30 in 1 BLISTER PACK</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>CALCIUM ACETATE 667mg in 1</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>MAGNESIUM STEARATE</item>
                     <item>SODIUM LAURYL SULFATE</item>
                     <item>FD&amp;C BLUE NO. 1</item>
                     <item>TITANIUM DIOXIDE</item>
                     <item>GELATIN</item>
                     <item>BUTYL ALCOHOL</item>
                     <item>PROPYLENE GLYCOL</item>
                     <item>SHELLAC</item>
                     <item>FERROSOFERRIC OXIDE</item>
                     <item>CROSPOVIDONE (120 .MU.M)</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="Remedy_Label"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250303"/>
               <component>
                  <observationMedia ID="Remedy_Label">
                     <text>Remedy_Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Remedy_Label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>